A2W-PHARMA-LTD
6.4.2022 18:02:11 CEST | Business Wire | Press release
A2W Pharma Ltd, a pharmaceutical company based in Malta, celebrates the opening of its new facility during a launch event on its premises today. The event is addressed by Hon. Miriam Dalli – Minister for Environment, Energy and Enterprise, H.E. Yu Dunhai – Ambassador of China to Malta, Peter Paul Farrugia - A2W Pharma Director, Antonio Sommei - Amino Chemicals CEO, and Kurt Farrugia - Malta Enterprise CEO, along with representatives from Malta Medicines Authority.
A2W provides full end to end processing from raw material to bottling with chemical and stability testing capabilities. The company has begun validating materials and methods, and is expecting to receive its EU-GMP certification this summer. Its long-term vision centres around the development of botanical active substances for pharmaceutical and nutraceutical product development.
“The opening of A2W Pharma is part of our strategic vision to extend the capabilities of our operations in Malta to support our partners in the development of pharmaceutical formulations,” says Antonio Sommei.
The mother company, ABA Chemicals Corp (Shenzen Stock Exchange 300261-CN:Shenzhen) has invested more than €6 million, through its API facility, Amino Chemicals Ltd, to address an immediate demand for EU-GMP certified extracts. Amino, also based in Malta, has 30 years of experience developing pharmaceutical APIs and lends its commercial and regulatory expertise.
“The discoveries related to the active substances found in the cannabis plant, and their therapeutic effects, represent a shift in the way patients suffering from various ailments can be treated. A2W’s vision is to increase access to these substances, whilst utilising 30 years of experience in pharmaceutical development to ensure adherence to the strictest of regulatory requirements,” says Tony Cai, ABA Chemicals Chairperson.
A2W’s long-term strategy centers around developing pharmaceutical products for therapeutic areas where there is a critical need to advance patient care. The medical cannabis industry, globally valued at USD 22 billion, is expected to continue its tremendous growth as more countries legalize prescription use to treat neurological and immunological conditions. Industry growth can be attributed to physician education and patient awareness regarding the benefits of medical cannabis.
“We are fortunate to have the support and expertise of ABA and Amino to help us achieve our goal of entering this new sector of pharmaceutical development, which we aim to enhance with our experience and capabilities,” says Peter Paul Farrugia.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220406005057/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Textron Aviation Marks 500th Cessna Citation Latitude Rollout22.9.2026 16:19:00 CEST | Press release
Milestone reinforces the Citation Latitude’s position as the world’s best-selling midsize business jet. Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, today announced the rollout of the 500th Cessna Citation Latitude business jet from the company’s Wichita, Kansas, manufacturing facility. The production milestone highlights the continued success of the world’s best-selling midsize business jet and recognizes the employees whose craftsmanship and dedication have helped make the Citation Latitude the trusted choice for operators around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922867287/en/ Textron Aviation marks 500th Cessna Citation Latitude rollout. (Photo Credit: Textron Aviation) “The rollout of the 500th Citation Latitude is a testament to the employees who build this aircraft with dedication and pride every day,” said Eric Cardinali, senior vice president, Manufacturing. “Behind every aircr
OCP Announces Date of Second Quarter and First Half 2026 Earnings22.9.2026 16:00:00 CEST | Press release
OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its second quarter and first half 2026 results on Tuesday, September 29, 2026. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 10:00 a.m. EDT, 2:00 p.m. Morocco (GMT) and 3:00 p.m. London time (GMT+1). OCP senior management will host a conference call to discuss second quarter and first half 2026 results at 11:00 a.m. EDT, 3:00 p.m. Morocco (GMT) and 4:00 p.m. London time (GMT+1) on Tuesday, September 29, 2026, for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma. About OCP OCP is a global leader in the fertilizer industry, backed by almost a century
Quaise Energy Selected for Up to $25 Million in U.S. Department of Energy Support to Advance World's First Commercial Superhot Geothermal Power Plant22.9.2026 15:30:00 CEST | Press release
Quaise's Project Obsidian, a commercial-scale superhot Enhanced Geothermal System (EGS), selected to receive federal funding as part of $99 million DOE effort to advance geothermal energy development across the United States Supports completion of the first well triplet at Project Obsidian, targeting more than 25 megawatts of gross electric power Project team includes Pacific Northwest National Laboratory, Lawrence Berkeley National Laboratory and Oregon State University Quaise Energy, a leading developer of utility-scale superhot geothermal energy, today announced that it has been selected by the U.S. Department of Energy (DOE) for up to $25 million in funding under the Next-Generation Geothermal Field Tests and Geothermal Resource Characterization and Confirmation funding opportunity. The support brings the U.S. closer to commercializing superhot Enhanced Geothermal Systems — technology that could unlock firm, clean power from hot rock beneath virtually any geography in the country.
Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 202622.9.2026 15:30:00 CEST | Press release
Late-Breaking Abstract to Feature New Data from First Phase 3 Registrational Study of Arcotatug Tavatecan in Previously Treated Advanced Gastric CancerTAK-928 Presentations Reinforce Potential in Patients with Immunotherapy-Resistant Non-Small Cell Lung Cancer (NSCLC) and Previously Untreated NSCLCTakeda Continues to Progress Clinical Development of Arcotatug Tavatecan and TAK-928; New Non-Squamous NSCLC Sub-Trial Added to Global Phase 3 MarsLight-11 Study Evaluating TAK-928 vs. Docetaxel Monotherapy Takeda(TSE:4502/NYSE:TAK)announced that new data from its oncology pipeline and portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress, taking place October 23-27, 2026, in Madrid, Spain. Key data will include a late-breaking abstract on arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343*) and two presentations on TAK-928 (Innovent R&D code: IBI363*). Clinical and real-world analyses of ALUNBRIG® (brigatinib) and FRUZAQLA® (fruquintinib) will also be
From CSR to Public Health Impact: How Colgate Bright Smiles, Bright Futures® is Driving Behavior Change for the Next Billion Children and Their Families22.9.2026 15:00:00 CEST | Press release
Colgate-Palmolive builds on its legacy of oral health, publishing an impact evaluation, evolving its health education tools rooted in behavior change, and scaling its global health partnerships. Colgate-Palmolive, the worldwide leader in oral care, announced a strategic evolution in its flagship oral health education program, Colgate Bright Smiles, Bright Futures® (BSBF), reflecting the Company’s commitment to global public health. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922129016/en/ Launched in 1991, the program has reached over two billion children and their families across more than 100 countries, demonstrating how private-sector commitment designed to support communities, can become a powerful force for public health, driving healthier behaviors and positive outcomes at scale. From health education curriculum and school programming to mobile dental vans and free oral health screenings, BSBF helps children and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom